Welcome to Cancer Hospital of the University of Chinese
Academy of Sciences (Zhejiang Cancer Hospital)
Founded in October 1963, Zhejiang Cancer Hospital (ZJCH) is one of the earliest four cancer specialized hospitals in China to maintain the highest standards of excellence in patient care, cancer prevention, research, education and rehabilitation and is ranked among the Top 10 Best Cancer Hospitals of China for 8 consecutive years. Under the cooperation framework agreement signed by Zhejiang Provincial Government and the Chinese Academy of Sciences (CAS) in May 2019, the construction of Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences and Hangzhou Medical College will be underway with the tremendous support of Zhejiang Cancer Hospital.
To deliver the highest quality health care to each patient and to provide every employee with the best care available, bearing the social responsibility as a public hospital.
To achieve the highest standards of excellence as a cancer specialized hospital both nationwide and worldwide.
Compassion Harmony Dedication Innovation
Patient care in 2019:
● over 606,435 outpatients, 60138 of whom were new patients,
● nearly 131,728 inpatient stays,
● approximately 22,977 surgerical operations,
● over 11,203 radiotherapy cases and 70,561 chemotherapy cases respectively.
The hospital gives top priority to discipline construction to remain at the forefront of medicine nationwide. With 2,289 inpatient beds, the hospital is home to 51 medical departments, including surgery, medical oncology, and radiation oncology,etc. The multidisciplinary cancer care teams (MDT) combine both the expertise and experience of numerous specialists to ensure the best possible treatment. The hospital was successfully designated by National Health Commission as the National Regional Cancer Center in 2019. Oncology has been developed as the National Key Clinical Specialty as well as the Key Medical Support Discipline of Zhejiang Province. Office for Cancer Prevention & Control of Zhejiang Province, Zhejiang Cancer Quality Control Center, and Zhejiang Clinical Pathology Quality Control Center are all affiliated to the hospital, together making great contributions to cancer treatment and prevention in China.
The hospital is devoted to educating the brightest medical minds, providing undergraduate and postgraduate education through its National Post-doctoral Workstation, standardized training for residents and specialist nursing and is named the national residency institution for oncology. The hospital has 2,275 employees and is home to scores of renowned and influential experts and scholars with an extraordinary depth and breadth of medical experiences, including academician of the CAS, chief scientists of the 973 Project (the National Program on Key Basic Research Project), chief scientists of the National Key R&D Program, Yangtze River Scholars & Distinguished Professor, etc.
The hospital holds dynamic research programs. Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences (CAS), the first oncology research institution established by the CAS outside city of Beijing, stands as the first comprehensive national-level life health research institution introduced by Zhejiang Province. Key laboratories are establshed to advance the current understanding of tumor:
● Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus) ,
● Zhejiang Key Laboratory of Radiation Oncology,
● Zhejiang Key Laboratory of Head & Neck Oncology Translational Medicine,
● Zhejiang Key Laboratory of Traditional Chinese and Western Medicine of Cancer.
Ranked as one of the largest cancer specimen banks in China, the hospital sets up a biological specimen bank reserving over 300,000 specimens. In addition, a National Clinical Trials Center where physicians participating in plenty of clinical research protocols annually identify more-effective cancer therapies.
The hospital has made great efforts to promote international exchange and cooperation. It has carried out extensive collaboration in academic exchanges, talent training, scientific research, etc. with international institutions such as MD Anderson Cancer Center, University of Hawaii Cancer Center, Duke University, National University of Singapore Medical School, Charité University Berlin and N.N. Blokhin National Medical Research Center of Oncology. Hangzhou International Symposium of Oncology (HISO), as a joint conference with MD Anderson Cancer Center, is one of the most influential international platform for academic exchange in the hospital. In 2016, the hospital was approved as Zhejiang International Science Technology Cooperation Base for Cancer Precision Treatment.
Last Updated: March 2020